Revised SPCs: ABASAGLAR (insulin glargine) 100 units/mL solution for injection in a pre-filled pen and cartridge

Injection technique information has been expanded in SPCs to advise continuous rotation of injection site to reduce risk of lipodystrophy and cutaneous amyloidosis and warn of potential risk of delayed insulin absorption following insulin injections at sites with these reactions.


electronic Medicines compendium